Drug Patent Watch
OCTOBER 28, 2024
The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. CDMOs provide a wide range of services that cater to the diverse needs of pharmaceutical companies, from early-stage development to commercial manufacturing.
STAT
OCTOBER 31, 2024
Teva Pharmaceutical, the world’s largest generic drugmaker, was fined $503 million by European antitrust regulators for delaying competition to a blockbuster multiple sclerosis medicine. The European Commission found the company had artificially extended the patent protection of Copaxone and systematically spread misleading information about a rival product.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
OCTOBER 28, 2024
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Express Pharma
OCTOBER 29, 2024
India’s pharmaceutical industry, the third largest globally by volume, plays a key role in improving global healthcare outcomes. The Covid-19 pandemic accelerated the digital transformation and underscored the importance of adaptability. In this evolving landscape, upskilling and reskilling have become essential as technological advancements, regulatory changes, and the demand for innovative healthcare solutions continue to grow.
STAT
OCTOBER 31, 2024
Barely 12 years after the publication of the first papers unveiling CRISPR-Cas9, a powerful enzyme for editing DNA, sickle cell patients are now receiving the first approved CRISPR-based medicine, Casgevy. Hundreds of patients with other inherited diseases, cancers, and chronic bacterial and viral infections are enrolled in clinical trials testing other CRISPR treatments.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
OCTOBER 31, 2024
The new Dementia Trials Accelerator is set to receive £20m of government funding
The Pharmacist
OCTOBER 29, 2024
Informal referrals to community pharmacies deprive pharmacies of more than £115 million each year, Community Pharmacy England (CPE) has estimated. This is the amount that would have been paid if existing referral routes had been used appropriately by GPs and NHS 111, rather than patients being signposted informally to their local community pharmacy.
STAT
OCTOBER 28, 2024
A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity. This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population.
PharmaVoice
OCTOBER 30, 2024
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Pharma Times
OCTOBER 31, 2024
Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020
The Pharmacist
OCTOBER 31, 2024
July 2024 saw the highest number of pharmacies meeting the Pharmacy First monthly threshold since it increased to 10 consultations in May, according to the latest Pharmacy First data. Nationally, clinical pathway consultations and urgent medicine supply referrals increased overall. But minor illness referrals decreased in July 2024. Scroll down for our interactive Pharmacy First […] The post See how your pharmacy compares as July Pharmacy First data released appeared first on The Pharmacis
STAT
OCTOBER 31, 2024
Of 104 reports of supply chain issues with dozens of drugs, meaningful shortages were 40% less likely to occur in Canada than in the U.S., a new study found, and the difference was largely attributed to the approach taken by the Canadian government to the problem. Between 2017 and 2021, regulators in the U.S. and Canada received the same number of reports about actual or potential shortages for the same 96 medicines.
PharmaVoice
NOVEMBER 1, 2024
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier. But there’s still hope in the pipeline.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
BioPharma Dive
OCTOBER 31, 2024
In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can significantly lower levels of amyloid in a Phase 3 trial.
The Pharmacist
OCTOBER 29, 2024
Pharmacies must contact all patients dispensed a specific batch of the beta blocker labetalol that may contain the wrong medication, the Medicines and Healthcare Products Regulatory Agency (MHRA) has instructed. If batch traceability is not possible, all patients dispensed this product in the last six months must be contacted. In a class two medicines recall […] The post Pharmacies must contact labetalol patients following manufacturing mix-up appeared first on The Pharmacist.
STAT
OCTOBER 30, 2024
All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs.
PharmaVoice
OCTOBER 31, 2024
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmaceutical Commerce
OCTOBER 31, 2024
With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.
Express Pharma
NOVEMBER 1, 2024
Oligonucleotides are at the forefront of modern medicine and have emerged as powerful tools in treating diseases in recent years. Oligonucleotides – short DNA or RNA molecules that host a range of applications in genetic testing, research, and forensics – have seen a marked growth in significance as therapeutics. As their clinical application widens, methods of production must be robust to ensure demand is met.
STAT
OCTOBER 29, 2024
Sen. Elizabeth Warren (D-Mass.) is urging the Federal Trade Commission to scrutinize recent deals from McKesson and Cardinal Health to buy oncology practices, saying those transactions pose “clear, anticompetitive risks.” McKesson, Cardinal Health, and Cencora are the three dominant wholesalers that distribute drugs and medical products.
PharmaVoice
OCTOBER 29, 2024
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
BioPharma Dive
NOVEMBER 1, 2024
The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm GLP-1s aren't a "silver bullet" for MASH, one analyst argued.
pharmaphorum
NOVEMBER 1, 2024
FDA advisors vote against Lexicon Pharma's type 1 diabetes and chronic kidney disease therapy sotagliflozin ahead of December verdict
STAT
OCTOBER 29, 2024
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of other therapies, the field of cancer vaccines was “seemingly dying,” Sullivan said.
Drug Patent Watch
OCTOBER 30, 2024
The pharmaceutical industry is known for its complex regulatory environment and lengthy product development processes. One often overlooked aspect of this industry is the potential benefits of abandoned and expired patents. These patents can provide opportunities for companies to bring new products to market at a lower cost and with reduced development time.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
BioPharma Dive
OCTOBER 30, 2024
Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital.
Express Pharma
NOVEMBER 1, 2024
Quality was once again in the spotlight at two recent industry meets. While regulators kept their sights on raising the compliance bar, industry chiefs pledged adherence to these codes. Not surprisingly, most speakers focused on the importance of trust. At the Indian Pharmaceutical Alliance’s (IPA) virtual 9th Advanced Good Manufacturing Practices (GMP) Workshop Dr Rajeev Raghuvanshi, Drugs Controller General of India, CDSCO, Government of India commented, “At the heart of the pharmaceutic
STAT
OCTOBER 31, 2024
After spending decades fixated on a single hypothesis, Alzheimer’s researchers are increasingly searching for new ways to combat the devastating neurologic disease. One such approach — precisely targeting the brain with magnetic pulses — got a boost when mid-stage trial data was presented Thursday. Scientists reported that patients with mild or moderate Alzheimer’s who received the therapy, known as transcranial magnetic stimulation (TMS), experienced a 44% slowing in
pharmaphorum
OCTOBER 28, 2024
MSD and Moderna start a third phase 3 trial of their V940 cancer vaccine, their second in early-stage lung cancer.
BioPharma Dive
OCTOBER 30, 2024
The partners no longer intend to develop Zurzuvae for one of the most common forms of depression, citing the time and cost of running new studies that would satisfy the FDA.
Expert insights. Personalized for you.
109 
Let's personalize your content